



Financial Tear Sheet

Corporate Profile

Cambrex Corporation is a custom development and manufacturing organization that specializes in products and services that accelerate the development and commercialization of small molecule therapeutics.

We offer APIs, advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.

Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage forms.

Primary IR Contact

Stephanie LaFiura
Investor Relations Associate
Phone: 201-804-3037
Fax: 201-804-9852
E-mail:
stephanie.lafiura@cambrex.com

Stock Performance

Symbol CBM (Common Stock)

Exchange NYSE (US Dollar)

Price \$58.42

Change (%) ▼ 1.81 (3.01%)

Volume 425,231

Data as of October 15, 2018 4:00 p.m. ET

Management

Steven M. Klosk President and Chief Executive Officer

Shawn P. Cavanagh Executive Vice President and Chief Operating Officer

Samantha M. Hanley Vice President, General Counsel and Secretary

Gregory P. Sargen Executive Vice President, Corporate Development and Strategy

Tom Vadaketh Executive Vice President and Chief Financial Officer

Recent Headlines & Events

There are currently no events scheduled.

Date	Title
October 08, 2018	Cambrex Invests c.\$3 Million to Upgrade Generic API Manufacturing Facilities at Milan, Italy Site
September 25, 2018	Cambrex to Expand and Invest at High Point, NC Site to Create New Center of Excellence for Process Development and Clinical Supply
September 12, 2018	Cambrex Completes Acquisition of Halo Pharma

SEC Filings

Filing Date	Form
September 18, 2018	8-K
September 05, 2018	4
August 21, 2018	4
August 10, 2018	8-K

Data provided by Nasdaq. Minimum 15 minutes delayed.